APO Research
Talk to an analyst

APO RESEARCH · REPORT

Gene Cell Therapy CDMO

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Gene Cell Therapy CDMO Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

4 January 2026199 pages

Choose your research edition.

Industry ResearchGene Cell Therapy CDMO Industry Research Report 2026128 pages · $2,950 USDIndustry Growth & TrendsGlobal Gene Cell Therapy CDMO Industry Growth and Trends Forecast to 2032113 pages · $3,450 USDMarket StructureGlobal Gene Cell Therapy CDMO Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Gene Cell Therapy CDMO Market Outlook and Growth Opportunities 2026206 pages · $4,250 USDMarket Analysis & ForecastGlobal Gene Cell Therapy CDMO Market Analysis and Forecast 2026-2032203 pages · $4,950 USD

Market perspective

The global Gene Cell Therapy CDMO market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The US & Canada market for Gene Cell Therapy CDMO is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Gene Cell Therapy CDMO is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Gene Cell Therapy CDMO is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Gene Cell Therapy CDMO is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Gene Cell Therapy CDMO include Catalent, Lonza, Charles River, Oxford Biomedica, Novartis, OBiO, GenScript, Pharmaron and Porton, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Includes

This report provides an overview of the global Gene Cell Therapy CDMO market and its size, analyzing global market trends based on historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Gene Cell Therapy CDMO and revenue in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Gene Cell Therapy CDMO revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering revenue and growth rates—for 2021-2032, and evaluates and forecasts the Gene Cell Therapy CDMO market size, projected growth trends, production technologies, key applications, and end-use industries.

Gene Cell Therapy CDMO Segment by Company

Catalent

Lonza

Charles River

Oxford Biomedica

Novartis

OBiO

GenScript

Pharmaron

Porton

Resilience

SK Pharmteco

Forge Biologics

Andelyn Biosciences

Roslin CT

eXmoor Pharma

Advanced Therapies

Catalent Biologics

Patheon Pharma Services

Gene Cell Therapy CDMO Segment by Type

Immune Cells

Stem Cell

Viral Vector

Plasmid DNA

Gene Cell Therapy CDMO Segment by Application

Pharmaceutical and Biotechnology Companies

Research and Academic Institutions

Hospital

Others

Gene Cell Therapy CDMO Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Gene Cell Therapy CDMO market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Gene Cell Therapy CDMO and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Gene Cell Therapy CDMO.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. Revenue of Gene Cell Therapy CDMO in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Gene Cell Therapy CDMO industry.

Chapter 3: Detailed analysis of Gene Cell Therapy CDMO companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Gene Cell Therapy CDMOrevenue, gross margin, and recent development, etc.

Chapter 7: North America (US & Canada) by type, by application and by country, revenue for each segment.

Chapter 8: Europe by type, by application and by country, revenue for each segment.

Chapter 9: China by type, and by application, revenue for each segment.

Chapter 10: Asia (excluding China) by type, by application and by region, revenue for each segment.

Chapter 11: South America, Middle East & Africa by type, by application and by country, revenue for each segment.

Chapter 12: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Gene Cell Therapy CDMO Market Size Growth Rate by Type (US$ Million): 2021 VS 2025 VS 2032 Table 2. Key Players of Immune Cells Table 3. Key Players of Stem Cell Table 4. Key Players of Viral Vector Table 3. Key Players of Plasmid DNA Table 4. Global Gene Cell Therapy CDMO Market Size Growth Rate by Application (US$ Million): 2021 VS 2025 VS 2032 Table 5. Key Players of Pharmaceutical and Biotechnology Companies Table 6. Key Players of Research and Academic Institutions Table 7. Key Players of Hospital Table 8. Key Players of Others Table 9. Global Gene Cell Therapy CDMO Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 10. Global Gene Cell Therapy CDMO Market Size by Region (2021-2026) & (US$ Million) Table 11. Global Gene Cell Therapy CDMO Market Share by Region (2021-2026) Table 12. Global Gene Cell Therapy CDMO Market Size by Region (2027-2032) & (US$ Million) Table 13. Global Gene Cell Therapy CDMO Market Share by Region (2027-2032) Table 14. Gene Cell Therapy CDMO Industry Trends Table 15. Gene Cell Therapy CDMO Industry Drivers Table 16. Gene Cell Therapy CDMO Industry Opportunities and Challenges Table 17. Gene Cell Therapy CDMO Industry Restraints Table 18. Global Gene Cell Therapy CDMO Revenue by Company (US$ Million) & (2021-2026) Table 19. Global Gene Cell Therapy CDMO Revenue Market Share by Company (2021-2026) Table 20. Global Gene Cell Therapy CDMO Players Revenue Ranking, 2024 VS 2025 VS 2026 Table 21. Global Gene Cell Therapy CDMO Key Company Head Office and Area Served Table 22. Global Gene Cell Therapy CDMO Company, Product Type & Application Table 23. Global Gene Cell Therapy CDMO Company Establishment Date Table 24. Global Company Market Concentration Ratio (CR5 and HHI) Table 25. Global Gene Cell Therapy CDMO by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 26. Global Gene Cell Therapy CDMO Market Size by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Gene Cell Therapy CDMO Market Size by Type (2021-2026) & (US$ Million) Table 28. Global Gene Cell Therapy CDMO Market Size by Type (2027-2032) & (US$ Million) Table 29. Global Gene Cell Therapy CDMO Revenue Market Share by Type (2021-2026) Table 30. Global Gene Cell Therapy CDMO Revenue Market Share by Type (2027-2032) Table 31. Global Gene Cell Therapy CDMO Market Size by Application 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Gene Cell Therapy CDMO Market Size by Application (2021-2026) & (US$ Million) Table 33. Global Gene Cell Therapy CDMO Market Size by Application (2027-2032) & (US$ Million) Table 34. Global Gene Cell Therapy CDMO Revenue Market Share by Application (2021-2026) Table 35. Global Gene Cell Therapy CDMO Revenue Market Share by Application (2027-2032) Table 36. Catalent Company Information Table 37. Catalent Business Overview Table 38. Catalent Gene Cell Therapy CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 39. Catalent Gene Cell Therapy CDMO Product Portfolio Table 40. Catalent Recent Development Table 41. Lonza Company Information Table 42. Lonza Business Overview Table 43. Lonza Gene Cell Therapy CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 44. Lonza Gene Cell Therapy CDMO Product Portfolio Table 45. Lonza Recent Development Table 46. Charles River Company Information Table 47. Charles River Business Overview Table 48. Charles River Gene Cell Therapy CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 49. Charles River Gene Cell Therapy CDMO Product Portfolio Table 50. Charles River Recent Development Table 51. Oxford Biomedica Company Information Table 52. Oxford Biomedica Business Overview Table 53. Oxford Biomedica Gene Cell Therapy CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 54. Oxford Biomedica Gene Cell Therapy CDMO Product Portfolio Table 55. Oxford Biomedica Recent Development Table 56. Novartis Company Information Table 57. Novartis Business Overview Table 58. Novartis Gene Cell Therapy CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 59. Novartis Gene Cell Therapy CDMO Product Portfolio Table 60. Novartis Recent Development Table 61. OBiO Company Information Table 62. OBiO Business Overview Table 63. OBiO Gene Cell Therapy CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 64. OBiO Gene Cell Therapy CDMO Product Portfolio Table 65. OBiO Recent Development Table 66. GenScript Company Information Table 67. GenScript Business Overview Table 68. GenScript Gene Cell Therapy CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 69. GenScript Gene Cell Therapy CDMO Product Portfolio Table 70. GenScript Recent Development Table 71. Pharmaron Company Information Table 72. Pharmaron Business Overview Table 73. Pharmaron Gene Cell Therapy CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 74. Pharmaron Gene Cell Therapy CDMO Product Portfolio Table 75. Pharmaron Recent Development Table 76. Porton Company Information Table 77. Porton Business Overview Table 78. Porton Gene Cell Therapy CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 79. Porton Gene Cell Therapy CDMO Product Portfolio Table 80. Porton Recent Development Table 81. Resilience Company Information Table 82. Resilience Business Overview Table 83. Resilience Gene Cell Therapy CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 84. Resilience Gene Cell Therapy CDMO Product Portfolio Table 85. Resilience Recent Development Table 86. SK Pharmteco Company Information Table 87. SK Pharmteco Business Overview Table 88. SK Pharmteco Gene Cell Therapy CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 89. SK Pharmteco Gene Cell Therapy CDMO Product Portfolio Table 90. SK Pharmteco Recent Development Table 91. Forge Biologics Company Information Table 92. Forge Biologics Business Overview Table 93. Forge Biologics Gene Cell Therapy CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 94. Forge Biologics Gene Cell Therapy CDMO Product Portfolio Table 95. Forge Biologics Recent Development Table 96. Andelyn Biosciences Company Information Table 97. Andelyn Biosciences Business Overview Table 98. Andelyn Biosciences Gene Cell Therapy CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 99. Andelyn Biosciences Gene Cell Therapy CDMO Product Portfolio Table 100. Andelyn Biosciences Recent Development Table 101. Roslin CT Company Information Table 102. Roslin CT Business Overview Table 103. Roslin CT Gene Cell Therapy CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 104. Roslin CT Gene Cell Therapy CDMO Product Portfolio Table 105. Roslin CT Recent Development Table 106. eXmoor Pharma Company Information Table 107. eXmoor Pharma Business Overview Table 108. eXmoor Pharma Gene Cell Therapy CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 109. eXmoor Pharma Gene Cell Therapy CDMO Product Portfolio Table 110. eXmoor Pharma Recent Development Table 111. Advanced Therapies Company Information Table 112. Advanced Therapies Business Overview Table 113. Advanced Therapies Gene Cell Therapy CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 114. Advanced Therapies Gene Cell Therapy CDMO Product Portfolio Table 115. Advanced Therapies Recent Development Table 116. Catalent Biologics Company Information Table 117. Catalent Biologics Business Overview Table 118. Catalent Biologics Gene Cell Therapy CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 119. Catalent Biologics Gene Cell Therapy CDMO Product Portfolio Table 120. Catalent Biologics Recent Development Table 121. Patheon Pharma Services Company Information Table 122. Patheon Pharma Services Business Overview Table 123. Patheon Pharma Services Gene Cell Therapy CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 124. Patheon Pharma Services Gene Cell Therapy CDMO Product Portfolio Table 125. Patheon Pharma Services Recent Development Table 126. North America Gene Cell Therapy CDMO Market Size by Type (2021-2026) & (US$ Million) Table 127. North America Gene Cell Therapy CDMO Market Size by Type (2027-2032) & (US$ Million) Table 128. North America Gene Cell Therapy CDMO Market Size by Application (2021-2026) & (US$ Million) Table 129. North America Gene Cell Therapy CDMO Market Size by Application (2027-2032) & (US$ Million) Table 130. North America Gene Cell Therapy CDMO Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 131. North America Gene Cell Therapy CDMO Market Size by Country (2021-2026) Table 132. North America Gene Cell Therapy CDMO Market Size by Country (2027-2032) Table 133. Europe Gene Cell Therapy CDMO Market Size by Type (2021-2026) & (US$ Million) Table 134. Europe Gene Cell Therapy CDMO Market Size by Type (2027-2032) & (US$ Million) Table 135. Europe Gene Cell Therapy CDMO Market Size by Application (2021-2026) & (US$ Million) Table 136. Europe Gene Cell Therapy CDMO Market Size by Application (2027-2032) & (US$ Million) Table 137. Europe Gene Cell Therapy CDMO Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 138. Europe Gene Cell Therapy CDMO Market Size by Country (2021-2026) Table 139. Europe Gene Cell Therapy CDMO Market Size by Country (2027-2032) Table 140. China Gene Cell Therapy CDMO Market Size by Type (2021-2026) & (US$ Million) Table 141. China Gene Cell Therapy CDMO Market Size by Type (2027-2032) & (US$ Million) Table 142. China Gene Cell Therapy CDMO Market Size by Application (2021-2026) & (US$ Million) Table 143. China Gene Cell Therapy CDMO Market Size by Application (2027-2032) & (US$ Million) Table 144. Asia Gene Cell Therapy CDMO Market Size by Type (2021-2026) & (US$ Million) Table 145. Asia Gene Cell Therapy CDMO Market Size by Type (2027-2032) & (US$ Million) Table 146. Asia Gene Cell Therapy CDMO Market Size by Application (2021-2026) & (US$ Million) Table 147. Asia Gene Cell Therapy CDMO Market Size by Application (2027-2032) & (US$ Million) Table 148. Asia Gene Cell Therapy CDMO Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 149. Asia Gene Cell Therapy CDMO Market Size by Country (2021-2026) Table 150. Asia Gene Cell Therapy CDMO Market Size by Country (2027-2032) Table 151. South America, Middle East & Africa Gene Cell Therapy CDMO Market Size by Type (2021-2026) & (US$ Million) Table 152. South America, Middle East & Africa Gene Cell Therapy CDMO Market Size by Type (2027-2032) & (US$ Million) Table 153. South America, Middle East & Africa Gene Cell Therapy CDMO Market Size by Application (2021-2026) & (US$ Million) Table 154. South America, Middle East & Africa Gene Cell Therapy CDMO Market Size by Application (2027-2032) & (US$ Million) Table 155. South America, Middle East & Africa Gene Cell Therapy CDMO Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 156. South America, Middle East & Africa Gene Cell Therapy CDMO Market Size by Country (2021-2026) Table 157. South America, Middle East & Africa Gene Cell Therapy CDMO Market Size by Country (2027-2032) Table 158. Research Programs/Design for This Report Table 159. Authors List of This Report Table 160. Secondary Sources Table 161. Primary Sources List of Figures Figure 1. Gene Cell Therapy CDMO Product Image Figure 2. Global Gene Cell Therapy CDMO Market Size Growth Rate by Type, 2021 VS 2025 VS 2032 (US$ Million) Figure 3. Global Gene Cell Therapy CDMO Market Share by Type: 2025 VS 2032 Figure 4. Immune Cells Image Figure 5. Stem Cell Image Figure 6. Viral Vector Image Figure 7. Plasmid DNA Image Figure 8. Global Gene Cell Therapy CDMO Market Size Growth Rate by Application, 2021 VS 2025 VS 2032 (US$ Million) Figure 9. Global Gene Cell Therapy CDMO Market Share by Application: 2025 VS 2032 Figure 10. Pharmaceutical and Biotechnology Companies Image Figure 11. Research and Academic Institutions Image Figure 12. Hospital Image Figure 13. Others Image Figure 14. Global Gene Cell Therapy CDMO Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 15. Global Gene Cell Therapy CDMO Market Size (2021-2032) & (US$ Million) Figure 16. Global Gene Cell Therapy CDMO Market Share by Region: 2025 VS 2032 Figure 17. Years Considered Figure 18. Global Gene Cell Therapy CDMO Market Share by Players in 2025 Figure 19. Global Top 5 and 10 Gene Cell Therapy CDMO Players Market Share by Revenue in 2025 Figure 20. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 21. Global Gene Cell Therapy CDMO Market Size by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 22. Global Gene Cell Therapy CDMO Revenue Market Share by Type (2021-2032) Figure 23. Global Gene Cell Therapy CDMO Market Size by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global Gene Cell Therapy CDMO Revenue Market Share by Application (2021-2032) Figure 25. North America Gene Cell Therapy CDMO Market Size (2021-2032) & (US$ Million) Figure 26. North America Gene Cell Therapy CDMO Market Share by Type (2021-2032) Figure 27. North America Gene Cell Therapy CDMO Market Share by Application (2021-2032) Figure 28. North America Gene Cell Therapy CDMO Market Share by Country (2021-2032) Figure 29. United States Gene Cell Therapy CDMO Market Size (2021-2032) & (US$ Million) Figure 30. Canada Gene Cell Therapy CDMO Market Size (2021-2032) & (US$ Million) Figure 31. Mexico Gene Cell Therapy CDMO Market Size (2021-2032) & (US$ Million) Figure 32. Europe Gene Cell Therapy CDMO Market Size (2021-2032) & (US$ Million) Figure 33. Europe Gene Cell Therapy CDMO Market Share by Type (2021-2032) Figure 34. Europe Gene Cell Therapy CDMO Market Share by Application (2021-2032) Figure 35. Europe Gene Cell Therapy CDMO Market Share by Country (2021-2032) Figure 36. Germany Gene Cell Therapy CDMO Market Size (2021-2032) & (US$ Million) Figure 37. France Gene Cell Therapy CDMO Market Size (2021-2032) & (US$ Million) Figure 38. U.K. Gene Cell Therapy CDMO Market Size (2021-2032) & (US$ Million) Figure 39. Italy Gene Cell Therapy CDMO Market Size (2021-2032) & (US$ Million) Figure 40. Russia Gene Cell Therapy CDMO Market Size (2021-2032) & (US$ Million) Figure 41. Nordic Countries Gene Cell Therapy CDMO Market Size (2021-2032) & (US$ Million) Figure 42. China Gene Cell Therapy CDMO Market Size (2021-2032) & (US$ Million) Figure 43. China Gene Cell Therapy CDMO Market Share by Type (2021-2032) Figure 44. China Gene Cell Therapy CDMO Market Share by Application (2021-2032) Figure 45. Asia Gene Cell Therapy CDMO Market Size (2021-2032) & (US$ Million) Figure 46. Asia Gene Cell Therapy CDMO Market Share by Type (2021-2032) Figure 47. Asia Gene Cell Therapy CDMO Market Share by Application (2021-2032) Figure 48. Asia Gene Cell Therapy CDMO Market Share by Country (2021-2032) Figure 49. Japan Gene Cell Therapy CDMO Market Size (2021-2032) & (US$ Million) Figure 50. South Korea Gene Cell Therapy CDMO Market Size (2021-2032) & (US$ Million) Figure 51. Taiwan Gene Cell Therapy CDMO Market Size (2021-2032) & (US$ Million) Figure 52. Southeast Asia Gene Cell Therapy CDMO Market Size (2021-2032) & (US$ Million) Figure 53. India Gene Cell Therapy CDMO Market Size (2021-2032) & (US$ Million) Figure 54. Australia Gene Cell Therapy CDMO Market Size (2021-2032) & (US$ Million) Figure 55. South America, Middle East & Africa Gene Cell Therapy CDMO Market Size (2021-2032) & (US$ Million) Figure 56. South America, Middle East & Africa Gene Cell Therapy CDMO Market Share by Type (2021-2032) Figure 57. South America, Middle East & Africa Gene Cell Therapy CDMO Market Share by Application (2021-2032) Figure 58. South America, Middle East & Africa Gene Cell Therapy CDMO Market Share by Country (2021-2032) Figure 59. Brazil Gene Cell Therapy CDMO Market Size (2021-2032) & (US$ Million) Figure 60. South Africa Gene Cell Therapy CDMO Market Size (2021-2032) & (US$ Million) Figure 61. Saudi Arabia Gene Cell Therapy CDMO Market Size (2021-2032) & (US$ Million) Figure 62. Turkey Gene Cell Therapy CDMO Market Size (2021-2032) & (US$ Million) Figure 63. Argentina Gene Cell Therapy CDMO Market Size (2021-2032) & (US$ Million) Figure 64. UAE Gene Cell Therapy CDMO Market Size (2021-2032) & (US$ Million) Figure 65. Egypt Gene Cell Therapy CDMO Market Size (2021-2032) & (US$ Million) Figure 66. Chile Gene Cell Therapy CDMO Market Size (2021-2032) & (US$ Million) Figure 67. Research Process Figure 68. Key Executives Interviewed

Scope & coverage.

Types
  • Immune Cells
  • Stem Cell
  • Viral Vector
  • Plasmid DNA
Applications
  • Pharmaceutical and Biotechnology Companies
  • Research and Academic Institutions
  • Hospital
  • Others
Companies covered
  • Catalent
  • Lonza
  • Charles River
  • Oxford Biomedica
  • Novartis
  • OBiO
  • GenScript
  • Pharmaron
  • Porton
  • Resilience
  • SK Pharmteco
  • Forge Biologics
  • Andelyn Biosciences
  • Roslin CT
  • eXmoor Pharma
  • Advanced Therapies
  • Catalent Biologics
  • Patheon Pharma Services

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Market Analysis by Type
  3. 1.2.1 Global Gene Cell Therapy CDMO Market Size Growth Rate by Type: 2021 VS 2025 VS 2032
  4. 1.2.2 Immune Cells
  5. 1.2.3 Stem Cell
  6. 1.2.4 Viral Vector
  7. 1.2.5 Plasmid DNA
  8. 1.3 Market Analysis by Application
  9. 1.3.1 Global Gene Cell Therapy CDMO Market Size Growth Rate by Application: 2021 VS 2025 VS 2032
  10. 1.3.2 Pharmaceutical and Biotechnology Companies
  11. 1.3.3 Research and Academic Institutions
  12. 1.3.4 Hospital
  13. 1.3.5 Others
  14. 1.4 Global Market Growth Prospects
  15. 1.5 Global Gene Cell Therapy CDMO Growth Trends by Region
  16. 1.5.1 Global Gene Cell Therapy CDMO Market Size by Region: 2021 VS 2025 VS 2032
  17. 1.5.2 Gene Cell Therapy CDMO Market Size by Region (2021-2026)
  18. 1.5.3 Gene Cell Therapy CDMO Market Size by Region (2027-2032)
  19. 1.6 Assumptions and Limitations
  20. 1.7 Study Goals and Objectives
  21. 1.8 Years Considered
2 Global Gene Cell Therapy CDMO Market Dynamics
  1. 2.1 Gene Cell Therapy CDMO Industry Trends
  2. 2.2 Gene Cell Therapy CDMO Industry Drivers
  3. 2.3 Gene Cell Therapy CDMO Industry Opportunities and Challenges
  4. 2.4 Gene Cell Therapy CDMO Industry Restraints
3 Competitive Landscape by Company
  1. 3.1 Global Gene Cell Therapy CDMO Revenue by Company (2021-2026)
  2. 3.2 Global Gene Cell Therapy CDMO Players Revenue Ranking, 2024 VS 2025 VS 2026
  3. 3.3 Global Gene Cell Therapy CDMO Key Company Head office and Area Served
  4. 3.4 Global Gene Cell Therapy CDMO Company, Product Type & Application
  5. 3.5 Global Gene Cell Therapy CDMO Company Establishment Date
  6. 3.6 Market Competitive Analysis
  7. 3.6.1 Global Gene Cell Therapy CDMO Market CR5 and HHI
  8. 3.6.2 Global Top 5 and 10 Gene Cell Therapy CDMO Players Market Share by Revenue in 2025
  9. 3.6.3 2025 Gene Cell Therapy CDMO Tier 1, Tier 2, and Tier 3
4 Gene Cell Therapy CDMO Market by Type
  1. 4.1 Global Gene Cell Therapy CDMO Market Size by Type (2021 VS 2025 VS 2032)
  2. 4.2 Global Gene Cell Therapy CDMO Market Size by Type (2021-2032)
  3. 4.3 Global Gene Cell Therapy CDMO Market Size Share by Type (2021-2032)
5 Gene Cell Therapy CDMO Market by Application
  1. 5.1 Global Gene Cell Therapy CDMO Market Size by Application (2021 VS 2025 VS 2032)
  2. 5.2 Global Gene Cell Therapy CDMO Market Size by Application (2021-2032)
  3. 5.3 Global Gene Cell Therapy CDMO Market Size Share by Application (2021-2032)
6 Company Profiles
  1. 6.1 Catalent
  2. 6.1.1 Catalent Company Information
  3. 6.1.2 Catalent Business Overview
  4. 6.1.3 Catalent Gene Cell Therapy CDMO Revenue and Gross Margin (US$ Million) & (2021-2026)
  5. 6.1.4 Catalent Gene Cell Therapy CDMO Product Portfolio
  6. 6.1.5 Catalent Recent Developments
  7. 6.2 Lonza
  8. 6.2.1 Lonza Company Information
  9. 6.2.2 Lonza Business Overview
  10. 6.2.3 Lonza Gene Cell Therapy CDMO Revenue and Gross Margin (US$ Million) & (2021-2026)
  11. 6.2.4 Lonza Gene Cell Therapy CDMO Product Portfolio
  12. 6.2.5 Lonza Recent Developments
  13. 6.3 Charles River
  14. 6.3.1 Charles River Company Information
  15. 6.3.2 Charles River Business Overview
  16. 6.3.3 Charles River Gene Cell Therapy CDMO Revenue and Gross Margin (US$ Million) & (2021-2026)
  17. 6.3.4 Charles River Gene Cell Therapy CDMO Product Portfolio
  18. 6.3.5 Charles River Recent Developments
  19. 6.4 Oxford Biomedica
  20. 6.4.1 Oxford Biomedica Company Information
  21. 6.4.2 Oxford Biomedica Business Overview
  22. 6.4.3 Oxford Biomedica Gene Cell Therapy CDMO Revenue and Gross Margin (US$ Million) & (2021-2026)
  23. 6.4.4 Oxford Biomedica Gene Cell Therapy CDMO Product Portfolio
  24. 6.4.5 Oxford Biomedica Recent Developments
  25. 6.5 Novartis
  26. 6.5.1 Novartis Company Information
  27. 6.5.2 Novartis Business Overview
  28. 6.5.3 Novartis Gene Cell Therapy CDMO Revenue and Gross Margin (US$ Million) & (2021-2026)
  29. 6.5.4 Novartis Gene Cell Therapy CDMO Product Portfolio
  30. 6.5.5 Novartis Recent Developments
  31. 6.6 OBiO
  32. 6.6.1 OBiO Company Information
  33. 6.6.2 OBiO Business Overview
  34. 6.6.3 OBiO Gene Cell Therapy CDMO Revenue and Gross Margin (US$ Million) & (2021-2026)
  35. 6.6.4 OBiO Gene Cell Therapy CDMO Product Portfolio
  36. 6.6.5 OBiO Recent Developments
  37. 6.7 GenScript
  38. 6.7.1 GenScript Company Information
  39. 6.7.2 GenScript Business Overview
  40. 6.7.3 GenScript Gene Cell Therapy CDMO Revenue and Gross Margin (US$ Million) & (2021-2026)
  41. 6.7.4 GenScript Gene Cell Therapy CDMO Product Portfolio
  42. 6.7.5 GenScript Recent Developments
  43. 6.8 Pharmaron
  44. 6.8.1 Pharmaron Company Information
  45. 6.8.2 Pharmaron Business Overview
  46. 6.8.3 Pharmaron Gene Cell Therapy CDMO Revenue and Gross Margin (US$ Million) & (2021-2026)
  47. 6.8.4 Pharmaron Gene Cell Therapy CDMO Product Portfolio
  48. 6.8.5 Pharmaron Recent Developments
  49. 6.9 Porton
  50. 6.9.1 Porton Company Information
  51. 6.9.2 Porton Business Overview
  52. 6.9.3 Porton Gene Cell Therapy CDMO Revenue and Gross Margin (US$ Million) & (2021-2026)
  53. 6.9.4 Porton Gene Cell Therapy CDMO Product Portfolio
  54. 6.9.5 Porton Recent Developments
  55. 6.10 Resilience
  56. 6.10.1 Resilience Company Information
  57. 6.10.2 Resilience Business Overview
  58. 6.10.3 Resilience Gene Cell Therapy CDMO Revenue and Gross Margin (US$ Million) & (2021-2026)
  59. 6.10.4 Resilience Gene Cell Therapy CDMO Product Portfolio
  60. 6.10.5 Resilience Recent Developments
  61. 6.11 SK Pharmteco
  62. 6.11.1 SK Pharmteco Company Information
  63. 6.11.2 SK Pharmteco Business Overview
  64. 6.11.3 SK Pharmteco Gene Cell Therapy CDMO Revenue and Gross Margin (US$ Million) & (2021-2026)
  65. 6.11.4 SK Pharmteco Gene Cell Therapy CDMO Product Portfolio
  66. 6.11.5 SK Pharmteco Recent Developments
  67. 6.12 Forge Biologics
  68. 6.12.1 Forge Biologics Company Information
  69. 6.12.2 Forge Biologics Business Overview
  70. 6.12.3 Forge Biologics Gene Cell Therapy CDMO Revenue and Gross Margin (US$ Million) & (2021-2026)
  71. 6.12.4 Forge Biologics Gene Cell Therapy CDMO Product Portfolio
  72. 6.12.5 Forge Biologics Recent Developments
  73. 6.13 Andelyn Biosciences
  74. 6.13.1 Andelyn Biosciences Company Information
  75. 6.13.2 Andelyn Biosciences Business Overview
  76. 6.13.3 Andelyn Biosciences Gene Cell Therapy CDMO Revenue and Gross Margin (US$ Million) & (2021-2026)
  77. 6.13.4 Andelyn Biosciences Gene Cell Therapy CDMO Product Portfolio
  78. 6.13.5 Andelyn Biosciences Recent Developments
  79. 6.14 Roslin CT
  80. 6.14.1 Roslin CT Company Information
  81. 6.14.2 Roslin CT Business Overview
  82. 6.14.3 Roslin CT Gene Cell Therapy CDMO Revenue and Gross Margin (US$ Million) & (2021-2026)
  83. 6.14.4 Roslin CT Gene Cell Therapy CDMO Product Portfolio
  84. 6.14.5 Roslin CT Recent Developments
  85. 6.15 eXmoor Pharma
  86. 6.15.1 eXmoor Pharma Company Information
  87. 6.15.2 eXmoor Pharma Business Overview
  88. 6.15.3 eXmoor Pharma Gene Cell Therapy CDMO Revenue and Gross Margin (US$ Million) & (2021-2026)
  89. 6.15.4 eXmoor Pharma Gene Cell Therapy CDMO Product Portfolio
  90. 6.15.5 eXmoor Pharma Recent Developments
  91. 6.16 Advanced Therapies
  92. 6.16.1 Advanced Therapies Company Information
  93. 6.16.2 Advanced Therapies Business Overview
  94. 6.16.3 Advanced Therapies Gene Cell Therapy CDMO Revenue and Gross Margin (US$ Million) & (2021-2026)
  95. 6.16.4 Advanced Therapies Gene Cell Therapy CDMO Product Portfolio
  96. 6.16.5 Advanced Therapies Recent Developments
  97. 6.17 Catalent Biologics
  98. 6.17.1 Catalent Biologics Company Information
  99. 6.17.2 Catalent Biologics Business Overview
  100. 6.17.3 Catalent Biologics Gene Cell Therapy CDMO Revenue and Gross Margin (US$ Million) & (2021-2026)
  101. 6.17.4 Catalent Biologics Gene Cell Therapy CDMO Product Portfolio
  102. 6.17.5 Catalent Biologics Recent Developments
  103. 6.18 Patheon Pharma Services
  104. 6.18.1 Patheon Pharma Services Company Information
  105. 6.18.2 Patheon Pharma Services Business Overview
  106. 6.18.3 Patheon Pharma Services Gene Cell Therapy CDMO Revenue and Gross Margin (US$ Million) & (2021-2026)
  107. 6.18.4 Patheon Pharma Services Gene Cell Therapy CDMO Product Portfolio
  108. 6.18.5 Patheon Pharma Services Recent Developments
7 North America
  1. 7.1 North America Gene Cell Therapy CDMO Market Size (2021-2032)
  2. 7.2 North America Gene Cell Therapy CDMO Market Size by Type
  3. 7.2.1 North America Gene Cell Therapy CDMO Market Size by Type (2021-2026)
  4. 7.2.2 North America Gene Cell Therapy CDMO Market Size by Type (2027-2032)
  5. 7.2.3 North America Gene Cell Therapy CDMO Market Share by Type (2021-2032)
  6. 7.3 North America Gene Cell Therapy CDMO Market Size by Application
  7. 7.3.1 North America Gene Cell Therapy CDMO Market Size by Application (2021-2026)
  8. 7.3.2 North America Gene Cell Therapy CDMO Market Size by Application (2027-2032)
  9. 7.3.3 North America Gene Cell Therapy CDMO Market Share by Application (2021-2032)
  10. 7.4 North America Gene Cell Therapy CDMO Market Size by Country
  11. 7.4.1 North America Gene Cell Therapy CDMO Market Size by Country (2021 VS 2025 VS 2032)
  12. 7.4.2 North America Gene Cell Therapy CDMO Market Size by Country (2021-2026)
  13. 7.4.3 North America Gene Cell Therapy CDMO Market Size by Country (2027-2032)
  14. 7.4.4 North America Gene Cell Therapy CDMO Market Share by Country (2021-2032)
  15. 7.4.5 United States
  16. 7.4.6 Canada
  17. 7.4.7 Mexico
8 Europe
  1. 8.1 Europe Gene Cell Therapy CDMO Market Size (2021-2032)
  2. 8.2 Europe Gene Cell Therapy CDMO Market Size by Type
  3. 8.2.1 Europe Gene Cell Therapy CDMO Market Size by Type (2021-2026)
  4. 8.2.2 Europe Gene Cell Therapy CDMO Market Size by Type (2027-2032)
  5. 8.2.3 Europe Gene Cell Therapy CDMO Market Share by Type (2021-2032)
  6. 8.3 Europe Gene Cell Therapy CDMO Market Size by Application
  7. 8.3.1 Europe Gene Cell Therapy CDMO Market Size by Application (2021-2026)
  8. 8.3.2 Europe Gene Cell Therapy CDMO Market Size by Application (2027-2032)
  9. 8.3.3 Europe Gene Cell Therapy CDMO Market Share by Application (2021-2032)
  10. 8.4 Europe Gene Cell Therapy CDMO Market Size by Country
  11. 8.4.1 Europe Gene Cell Therapy CDMO Market Size by Country (2021 VS 2025 VS 2032)
  12. 8.4.2 Europe Gene Cell Therapy CDMO Market Size by Country (2021-2026)
  13. 8.4.3 Europe Gene Cell Therapy CDMO Market Size by Country (2027-2032)
  14. 8.4.4 Europe Gene Cell Therapy CDMO Market Share by Country (2021-2032)
  15. 8.4.5 Germany
  16. 8.4.6 France
  17. 8.4.7 U.K.
  18. 8.4.8 Italy
  19. 8.4.9 Russia
  20. 8.4.10 Nordic Countries
9 China
  1. 9.1 China Gene Cell Therapy CDMO Market Size (2021-2032)
  2. 9.2 China Gene Cell Therapy CDMO Market Size by Type
  3. 9.2.1 China Gene Cell Therapy CDMO Market Size by Type (2021-2026)
  4. 9.2.2 China Gene Cell Therapy CDMO Market Size by Type (2027-2032)
  5. 9.2.3 China Gene Cell Therapy CDMO Market Share by Type (2021-2032)
  6. 9.3 China Gene Cell Therapy CDMO Market Size by Application
  7. 9.3.1 China Gene Cell Therapy CDMO Market Size by Application (2021-2026)
  8. 9.3.2 China Gene Cell Therapy CDMO Market Size by Application (2027-2032)
  9. 9.3.3 China Gene Cell Therapy CDMO Market Share by Application (2021-2032)
10 Asia (Excluding China)
  1. 10.1 Asia Gene Cell Therapy CDMO Market Size (2021-2032)
  2. 10.2 Asia Gene Cell Therapy CDMO Market Size by Type
  3. 10.2.1 Asia Gene Cell Therapy CDMO Market Size by Type (2021-2026)
  4. 10.2.2 Asia Gene Cell Therapy CDMO Market Size by Type (2027-2032)
  5. 10.2.3 Asia Gene Cell Therapy CDMO Market Share by Type (2021-2032)
  6. 10.3 Asia Gene Cell Therapy CDMO Market Size by Application
  7. 10.3.1 Asia Gene Cell Therapy CDMO Market Size by Application (2021-2026)
  8. 10.3.2 Asia Gene Cell Therapy CDMO Market Size by Application (2027-2032)
  9. 10.3.3 Asia Gene Cell Therapy CDMO Market Share by Application (2021-2032)
  10. 10.4 Asia Gene Cell Therapy CDMO Market Size by Country
  11. 10.4.1 Asia Gene Cell Therapy CDMO Market Size by Country (2021 VS 2025 VS 2032)
  12. 10.4.2 Asia Gene Cell Therapy CDMO Market Size by Country (2021-2026)
  13. 10.4.3 Asia Gene Cell Therapy CDMO Market Size by Country (2027-2032)
  14. 10.4.4 Asia Gene Cell Therapy CDMO Market Share by Country (2021-2032)
  15. 10.4.5 Japan
  16. 10.4.6 South Korea
  17. 10.4.7 Taiwan
  18. 10.4.8 Southeast Asia
  19. 10.4.9 India
  20. 10.4.10 Australia
11 South America, Middle East & Africa
  1. 11.1 South America, Middle East & Africa Gene Cell Therapy CDMO Market Size (2021-2032)
  2. 11.2 South America, Middle East & Africa Gene Cell Therapy CDMO Market Size by Type
  3. 11.2.1 South America, Middle East & Africa Gene Cell Therapy CDMO Market Size by Type (2021-2026)
  4. 11.2.2 South America, Middle East & Africa Gene Cell Therapy CDMO Market Size by Type (2027-2032)
  5. 11.2.3 South America, Middle East & Africa Gene Cell Therapy CDMO Market Share by Type (2021-2032)
  6. 11.3 South America, Middle East & Africa Gene Cell Therapy CDMO Market Size by Application
  7. 11.3.1 South America, Middle East & Africa Gene Cell Therapy CDMO Market Size by Application (2021-2026)
  8. 11.3.2 South America, Middle East & Africa Gene Cell Therapy CDMO Market Size by Application (2027-2032)
  9. 11.3.3 South America, Middle East & Africa Gene Cell Therapy CDMO Market Share by Application (2021-2032)
  10. 11.4 South America, Middle East & Africa Gene Cell Therapy CDMO Market Size by Country
  11. 11.4.1 South America, Middle East & Africa Gene Cell Therapy CDMO Market Size by Country (2021 VS 2025 VS 2032)
  12. 11.4.2 South America, Middle East & Africa Gene Cell Therapy CDMO Market Size by Country (2021-2026)
  13. 11.4.3 South America, Middle East & Africa Gene Cell Therapy CDMO Market Size by Country (2027-2032)
  14. 11.4.4 South America, Middle East & Africa Gene Cell Therapy CDMO Market Share by Country (2021-2032)
  15. 11.4.5 Brazil
  16. 11.4.6 South Africa
  17. 11.4.7 Saudi Arabia
  18. 11.4.8 Turkey
  19. 11.4.9 Argentina
  20. 11.4.9 UAE
  21. 11.4.9 Egypt
  22. 11.4.9 Chile
12 Concluding Insights
    13 Appendix
    1. 13.1 Reasons for Doing This Study
    2. 13.2 Research Methodology
    3. 13.3 Research Process
    4. 13.4 Authors List of This Report
    5. 13.5 Data Source
    6. 13.5.1 Secondary Sources
    7. 13.5.2 Primary Sources
    8. 13.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst